{"filing":{"accession_number":"0001104659-26-103720","cik":"0001768946","ticker":null,"company_name":"Biophytis SA","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"tm2624379d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768946/000110465926103720/tm2624379d1_6k.htm"},"events":[{"id":30557,"run_id":28005,"accession_number":"0001104659-26-103720","anchor_item_number":"EX-99.1","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This exhibit discloses a material financial restructuring combining warrant exercise proceeds (€2.5M), debt drawdowns (€1.2M), and debt-to-equity conversion (€1.4M) that strengthens cash position to €3.0M and extends runway into Q1 2027. While the disclosure includes operational updates (Phase 2 obesity study, Hong Kong JV), the primary substance is financial restructuring and capital management—a material financial event that does not fit the specific categories of debt_issuance (no new debt created), dilutive_issuance (warrant exercise is not an unregistered sale), or dividend_distribution. The 30% debt reduction and cash runway extension would affect a reasonable investor's assessment of the registrant's financial viability.","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33181,"accession_number":"0001104659-26-103720","item_number":"EX-99.1","item_title":"tm2624379d1_ex99-1.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses a material financial restructuring combining warrant exercise proceeds (€2.5M), debt drawdowns (€1.2M), and debt-to-equity conversion (€1.4M) that strengthens cash position to €3.0M and extends runway into Q1 2027. While the disclosure includes operational updates (Phase 2 obesity study, Hong Kong JV), the primary substance is financial restructuring and capital management—a material financial event that does not fit the specific categories of debt_issuance (no new debt created), dilutive_issuance (warrant exercise is not an unregistered sale), or dividend_distribution. The 30% debt reduction and cash runway extension would affect a reasonable investor's assessment of the registrant's financial viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T16:34:59.902275+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33181,"accession_number":"0001104659-26-103720","item_number":"EX-99.1","item_title":"tm2624379d1_ex99-1.htm","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses a material financial restructuring combining warrant exercise proceeds (€2.5M), debt drawdowns (€1.2M), and debt-to-equity conversion (€1.4M) that strengthens cash position to €3.0M and extends runway into Q1 2027. While the disclosure includes operational updates (Phase 2 obesity study, Hong Kong JV), the primary substance is financial restructuring and capital management—a material financial event that does not fit the specific categories of debt_issuance (no new debt created), dilutive_issuance (warrant exercise is not an unregistered sale), or dividend_distribution. The 30% debt reduction and cash runway extension would affect a reasonable investor's assessment of the registrant's financial viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T16:34:59.902275+00:00","company_name":"Biophytis SA","ticker":null,"filing_date":"2026-08-31"}]}